Rifampin

Publisher Website
Google Scholar
Abstract
In a double blind study in naval recruits, rifampin reduced the percentage of meningococcal carriers by 80%, compared with controls. It was well tolerated in four daily 600-mg doses. Levels of rifampin in serum samples exceeded the minimal inhibitory concentration (MIC) of rifampin required to inhibit meningococci vitro. Rifampin levels in saliva exceeded the MIC for all meningococcal reference strains tested in vitro at 3.5 hours after a third 600-mg daily dose. At 6.5 hours after a fourth 600-mg dose, the range of rifampin levels in saliva samples extended above and below the range of MIC of rifampin for the reference strains. The efficacy of rifampin in the eradication of the meningococcal carrier state has been established. It should prove safe and effective in carriers of sulfadiazine-resistant meningococci under limited conditions.

This publication has 6 references indexed in Scilit: